Posted by Michael Wonder on 12 Sep 2024
Ilya Pharma receives rare paediatric disease designation from the US FDA for emilimogene sigulactibac for the treatment of skin wounds in SAVI patients
11 September 2024 - Ilya Pharma today announced that it has received rare paediatric disease designation by the US FDA.
The rationale for investigating topical emilimogene sigulactibac for the treatment of skin wounds in patients with SAVI is based on the results from previous published non-clinical and clinical studies showing 1) Accelerated wound healing, 2) Increased numbers of CXCR4-expressing tissue restorative macrophages in injured tissue improve vessel function and tissue restoration, and 3) Potent antimicrobial effects on bacterial wound pathogens, especially multi drug resistant bacteria.
